ImmunoBiochem partners with CCAB to advance new antibody-drug conjugates
April 18, 2016 – ImmunoBiochem Corporation, a Canadian biopharmaceutical company developing novel Antibody Drug Conjugates (ADCs), has partnered with CCAB to develop new therapeutics for cancer treatment. CCAB will be supporting the development of fully-human therapeutic antibodies against ImmunoBiochem’s lead cancer target, and ImmunoBiochem will then engineer the new antibodies into ADCs and take the new molecules into pre-clinical trials and into the clinic.
“We are pleased to support ImmunoBiochem with our extensive antibody engineering expertise and pave the way for ADC therapeutics powered by our synthetic antibodies” said Dr. Sachdev Sidhu, CCAB CEO.
“ImmunoBiochem’s lead target is a valuable cancer biomarker that is validated by a wealth of clinical data. The investment from CCAB helps us rapidly move from proof-of-concept to development-ready therapeutic candidates by tapping into state-of-the-art synthetic antibody technologies” said Dr. Anton Neschadim, President and CEO of ImmunoBiochem.
Read the full press release here.
For more information about ImmunoBiochem, contact: Anton Neschadim , ImmunoBiochem Corporation President & CEO | +1 (416) 897-2789 | email@example.com